Abstract Search

8.13. GnRH antagonist treatment of malignant adrenocortical tumors

M Doroszko , M Chrusciel , J Stelmaszewska , T Slezak , S Anisimowicz , U Plockinger , M Quinkler , M Bonomi , S Wolczynski , I Huhtaniemi , J Toppari , NA Rahman

To read the full abstract: Endocr Relat Cancer. 2019; 26(1): 103117.Incidence of adrenocortical carcinomas shows a bimodal distribution, being more common in children <10 years and in adults aged 4050 years. Their prognosis is poor, with only 1025% 5-year survival. Ectopic expression of LHCGR and GNRHR has been reported in ACTH-independent adrenal hyperplasia ...

0 shares

ey0017.8-4 | Important for Clinical Practice | ESPEYB17

8.4. Long-term outcome of primary bilateral macronodular adrenocortical hyperplasia after unilateral adrenalectomy

A Osswald , M Quinkler , G Di Dalmazi , T Deutschbein , G Rubinstein , K Ritzel , S Zopp , J Bertherat , F Beuschlein , M Reincke

To read the full abstract: J Clin Endocrinol Metab. 2019; 104(7): 29852993. PMID: 30844071.Endogenous Cushing syndrome (CS) is a severe condition characterized by excessive glucocorticoid production (1). In 20% of cases, cortisol is secreted autonomously by the adrenal cortex (2). Adrenal CS is mostly caused by unilateral cortisol-producing adrenal ad...

0 shares

ESPE Yearbook of Paediatric Endocrinology

8.13. GnRH antagonist treatment of malignant adrenocortical tumors

8.4. Long-term outcome of primary bilateral macronodular adrenocortical hyperplasia after unilateral adrenalectomy

BiosciAbstracts